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تصوير اجلسم باستخدام مسح الغاليوم-67 يف عصر التصوير املقطعي باإلصدار 
البوزيرتوين والتصوير املقطعي
جتربة مركز رعاية ثالثية
بدرية ال�سقرية و نعيمة البلو�سية
abstract: Objectives: Although 18F-fluorodeoxyglucose positron emission tomography (PET)/computed 
tomography (CT) has largely replaced the use of gallium-67 (67Ga) scintigraphy in the evaluation and follow-up 
of lymphoma patients, 67Ga scans are still of value, particularly in countries where no PET/CT service is available. 
The current study presents the experience of a tertiary care centre using 67Ga scintigraphy for the evaluation of 
lymphomas and infections. Methods: A retrospective review was conducted of all 67Ga scans performed between 
2007 and 2011 at the Royal Hospital in Muscat, Oman. Images and reports of 67Ga scans were compared to clinical 
and radiological follow-up data including CT and PET/CT scans and biopsies when available. Results: A total of 74 
patients were referred for 67Ga scintigraphy during this period with 12 patients excluded due to lack of follow-up 
data, resulting in 62 patients. Among these patients, 90 67Ga scans were performed, including 59 for lymphoma, 29 
for infection and two for sarcoidosis assessment. Of the infection assessment scans, 22 were performed to assess 
pyrexia of unknown origin and seven for follow-up after known infections. Sensitivity and specificity were found to 
be 80% and 88%, respectively, for the lymphoma assessment scans. For the infection assessment scans, sensitivity 
and specificity were reported to be 80% and 100%, respectively. Conclusion: Results from this study were consistent 
with other reported rates of 67Ga scan sensitivity and specificity in the evaluation of lymphomas and infections. This 
indicates that 67Ga scintigraphy is a useful tool for these types of evaluations when PET/CT services are not available.
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اإىل  18F-fluorodeoxyglucose قد حل  البوزيرتوين/الت�سوير املقطعي  بالإ�سدار  الت�سوير املقطعي  اأن  الرغم من  الهدف: على  امللخ�ص: 
حد كبري حمل م�سح اجل�سم باإ�ستخدام الغاليومـ-67Ga( 67( يف تقييم ومتابعة مر�سى �رسطان الغدد الليمفاوية، اإل اأن م�سح 67Ga ل يزال 
ذي قيمة، ول �سيما يف البلدان التي تكون فيها خدمة PET/CT غري متاحة. تقدم الدرا�سة احلالية جتربة مركز رعاية ثالثية يف ا�ستخدام 
 67Ga اأجري لها م�سح  اأجرى ا�ستعرا�س باأثر رجعي جلميع احلالت التي  الطريقة:  67Ga لتقييم الأورام اللمفاوية واللتهابات.  م�سوحات 
املتابعة  لبيانات   67Ga م�سح  وتقارير  مقارنة �سور  �سلطنة عمان. ومتت  م�سقط،  ال�سلطاين يف  امل�ست�سفى  2011 يف  و   2007 عامي  بني 
النتائج: مت  ال�رسيرية وتقارير الشعة املقطعية وتقارير الت�سوير املقطعي باإل�سدار البوزيرتوين ونتائج اخلزعات عندما تكون متاحة. 
حتويل ما جمموعه 74 مري�سا مل�سح اجل�سم با�ستخدام 67Ga خالل هذه الفرتة. مت ا�ستبعاد 12 مري�سا نظرا لعدم وجود بيانات املتابعة، 
فكان املجموع املتبقي 62 مري�سا اأجري لهم ما جمموعه 90 م�سحا با�ستخدام 67Ga، مبا يف ذلك 59 م�سحا ل�رسطان الغدد الليمفاوية، 29 
م�سحا للعدوى واثنان لتقييم مر�س ال�ساركويد. اأو�سحت النتائج اأن احل�سا�سية واخل�سو�سية مل�سح 67Ga لتقييم �رسطان الغدد الليمفاوية 
كان %88 و %80 على التوايل، و %100 و %80 مل�سح تقييم العدوى على التوايل. اخلال�صة: كانت نتائج هذه الدرا�سة تتفق مع الدرا�سات 
الخرى التي اأجريت لنف�س الغر�س. وهذا يدل على اأن م�سح اجل�سم با�ستخدام 67Ga هو اأداة مفيدة لهذه الأنواع من التقييمات يف املناطق 
التي ل تتوافر فيها خدمات.
مفتاح الكلمات: الغاليوم -67- �سيرتيت؛ النظائر امل�سعة للغاليوم؛ فلورايد-18 فلوروديوك�سيجلوكوز؛ م�سح اجل�سم؛ �رسطان الغدد الليمفاوية؛ 
عدوى؛ حمى غري معروفة املن�ساأ؛ �سلطنة عمان.
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Advances in Knowledge
- Results of the current study confirmed that the sensitivity and specificity of gallium-67 (67Ga) scintigraphy in this tertiary centre were 
consistent with those reported in the international literature. 
Application to Patient Care
- 67Ga scintigraphy can help in localising the foci of infection. Scans can also show positive findings in patients with neoplastic disease 
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The clinical impact and cost-effect-iveness of combined 18F-fludeoxyglucose (18F-FDG) positron emission tomography 
(PET) and computed tomography (CT) is well 
documented in the literature and this technology has 
a wide range of applications in both benign diseases 
and oncology.1 Additionally, the role of PET/CT in 
the diagnosis and management of lymphomas has 
been well established for more than a decade.2 Non-
PET radiotracers that were previously used for the 
evaluation of lymphomas and infections are now 
seldom utilised in current practice. However, despite 
the advances this technology has brought to patient 
management, some centres still lack PET/CT facilities. 
In other institutions where PET/CT is available, not 
all PET radiotracers are accessible or approved for 
clinical practice. Hence, the old radiotracers used in 
nuclear medicine still exist and play a role in today’s 
modern practice. 
One of the most commonly used radioisotopes 
in tumour imaging, as well as in the imaging of 
infection and inflammation, is gallium-67 citrate 
(67Ga).3 This group IIIA metal has been used for 
decades for the imaging of various solid neoplasms, 
particularly lymphomas, and in the investigation 
of acute inflammatory conditions. It is also used to 
assess infections and to identify the site of disease 
in patients with pyrexia of unknown origin (PUO).4 
67Ga is produced by cyclotron and has a half-life of 
78.26 hours and energy abundances of 93 kilo electron 
volts ([keV] 40%), 184 keV (20%), 300 keV (17%) or 
393 keV (5%). For medical radiology purposes, 67Ga is 
provided in the form of a sterile solution of gallium 
citrate.3,5,6 The human body reacts to 67Ga similarly to 
the way that it handles ferric iron. Gallium III ions bind 
to transferrin glycoproteins, leukocyte lactoferrin, 
bacterial siderophores, inflammatory proteins and cell 
membranes in neutrophils and become concentrated 
in areas of inflammation and rapid cell division.3,7 
This retrospective study aimed to evaluate the use 
of 67Ga in a tertiary care hospital over a period of five 
years and compare outcomes with available clinical 
and radiological follow-up data, including CT and 
PET/CT scans and biopsies. 
Methods
This retrospective review included all 67Ga scintigraphy 
scans performed in the Department of Nuclear 
Medicine at the Royal Hospital, Muscat, Oman, from 
2007–2011. Only patients who were referred to this 
department and with follow-up appointments at the 
Royal Hospital were included in the study. 
At the Royal Hospital, 67Ga scans were performed 
by nuclear medicine technologists with a Siemens 
E-Cam Dual-Head Variable Angle Gamma Camera 
(Siemens Medical Solutions USA Inc., Malvern, 
Pennsylvania, USA). Adult patients undergoing 67Ga 
scintigraphy received a dose of 180 megabecquerels 
(MBq) while the dose for child patients was calculated 
by multiplying their weight in kg by 180 MBq and 
dividing the total by 70 kg.8 All patients with excessive 
bowel activity were given laxatives and scanned 
one or two days afterward. Whole body imaging for 
lymphoma patients was performed 48 hours after the 
67Ga injection using both detectors with a matrix size 
of 256 x 1,024 pixels. However, patients with PUO or 
infections were imaged 24 hours after the injection. 
Additional imaging was performed after 48 hours or 
later, if deemed necessary. 
Spot views of the chest and abdomen were 
acquired with both detectors with a matrix size of 256 x 
256 pixels. Imaging was halted either after five minutes 
had elapsed or if 500 kilo counts had been obtained. 
The whole process usually took 30–45 minutes, 
although sometimes longer if single photon emission 
CT images were also required. 
The 67Ga images and reports were compared to 
subsequent clinical and radiological follow-up data, 
including CT and PET/CT scans and biopsies, if 
available. These data were collected from hospital 
records retrospectively. 
This study was approved by the Research & Ethical 
Committee at the Royal Hospital (#MESRC 17/2014).
Results
A total of 74 patients were referred to the Department 
of Nuclear Medicine at the Royal Hospital for 67Ga 
scintigraphy between 2007 and 2011; however, 12 
presenting with pyrexia of unknown origin. Follow-up 67Ga scans can be performed to assess the response to treatment or resolution of 
the infective process.
- Despite current hybrid and molecular imaging services provided by combined 18F-fluorodeoxyglucose positron emission tomography 
and computed tomography, this study demonstrated that 67Ga scintigraphy remains a useful tool for the evaluation and follow-up of 
patients with lymphoma.
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Figure 1: Gallium-67 scintigraphy images revealing pericardial uptake (arrows) in a patient with pyrexia of unknown 
origin. Echocardiography and aspiration revealed tuberculosis (TB) pericarditis. The patient was subsequently treated 
with anti-TB medication. 
RT = right; LT = left.
for sarcoidosis. Of the 67Ga scans carried out for 
lymphoma patients, 32 were for Hodgkin’s lymphomas 
(HL), 23 were for non-Hodgkin’s lymphomas (NHL), 
three were for mucosa-associated lymphoid tissue 
lymphomas and one was for T cell lymphoma.
Lymphoma scans were divided into six baseline 
scans, 10 mid-therapy response assessment scans and 
43 post-therapy scans for the assessment of relapse 
[Table 1]. Of the six baseline studies, five scans yielded 
true-positive results and one showed a false-negative 
result. Of the 10 mid-therapy studies performed to 
assess response to therapy, six were true-negative, 
three were true-positive and one yielded a false-
negative result. The majority of the 67Ga lymphoma 
scans were performed to assess relapse: 24 scans 
yielded true-negative results (i.e. no evidence of 
gallium-avid lesions); 11 scans produced true-positive 
patients were excluded due to a lack of follow-up 
data. As a result, 62 patients were included in the 
final sample. The mean age of these patients was 43 
years old. A total of 28 patients were male (45%). The 
majority of referrals were from medical oncologists 
referring lymphoma patients (n = 24; 39%) and 
infectious diseases specialists referring patients (n = 9; 
15%), primarily for the localisation of infection sites. 
Seven patients (11%) were paediatric haematology 
cases; the remaining patients were chest medicine, 
paediatric, rheumatology, nephrology, neurology or 
acute medicine cases. 
A total of 90 67Ga scans were performed during the 
study period. Assessment of lymphomas constituted 
the bulk of the referrals, with a total of 59 scans (66%). 
Of the remaining scans, 29 (32%) were performed for 
infection assessment and two (2%) were performed 
Table 1: Comparison of the findings of gallium-67 
scintigraphy lymphoma assessment scans to subsequent 












Baseline 5 0 0 1 6
Mid-
therapy
3 0 6 1 10
Post-
therapy
11 5 24 3 43
Total 19 5 30 5 59
Table 2: Comparison of the findings of gallium-67 
scintigraphy infection assessment scans to subsequent 
















5 2 0 0 7
Total 17 9 0 3 29
PUO = pyrexia of unknown origin.
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results (either recurrence in the same sites or relapses 
in new sites); and five scans gave false-positive results 
(infection sites which were mistaken for lymphoma 
lesions). The remaining three scans yielded false-
negative results as the lesions were not avid on 67Ga 
scans but were positive on a subsequent 18F-FDG-
PET/CT scan or via biopsy. These results indicated a 
sensitivity and specificity of 80% and 88%, respectively, 
for assessing lymphomas using 67Ga scintigraphy. 
Infection assessments were carried out either for 
patients with PUO in order to localise the source 
of infection (n = 22) or for follow-up of a known 
infection (n = 7) [Table 2]. For known infection follow-
up scans, five yielded true-positive results while two 
yielded true-negative results. Of the 22 patients who 
were scanned for PUO, nine indicated positive uptake 
at different sites and these areas were subsequently 
targeted during treatment. One of these patients had a 
positive 24-hour whole body 67Ga scan with pericardial 
uptake indicating active pericarditis, which turned out 
to be secondary to tuberculosis [Figure 1]. A further 
three patients were found to have 67Ga-avid lesions. 
Of the three, one patient showed suprarenal uptake, 
with a biopsy revealing neuroblastoma [Figure 2]. 
The second patient had supraclavicular lymph node 
uptake revealing HL [Figure 3], while the third 
patient showed lung uptake which was found to be 
Wegener’s granulomatosis.
There were no 67Ga-avid lesions found in the 
remaining 10 PUO assessment scans. In three patients, 
no source of infection was found and the patients 
were treated empirically with antibiotics. In another 
three patients, the negative scans were attributed to 
prolonged antibiotic therapy (n = 2) and fungal infection 
(n = 1). In the final four negative 67Ga scans, no source 
of infection was found and the fevers were attributed 
to different disease processes, including systemic lupus 
erythematosus, adult-onset Still’s disease, a connective 
tissue disease and myelodysplastic syndrome. These 
results showed sensitivity and specificity rates of 80% 
and 100%, respectively, in the assessment of infection 
using 67Ga scintigraphy.
Two patients were known to have sarcoidosis and 
were referred for an assessment of disease activity. 
One was negative with no 67Ga-avid uptake related to 
 
Figure 2: Gallium-67 scintigraphy images showing 
left suprarenal uptake (arrows) in a child with pyrexia 
of unknown origin. Computed tomography and a 
subsequent biopsy revealed a neuroblastoma.
RT = right; LT = left.
 
Figure 3: Gallium-67 scintigraphy images showing mediastinal (red arrow) and thymic uptake (blue arrow) in a patient 
referred for lymphoma assessment. A biopsy revealed Hodgkin’s lymphoma.
RT = right; LT = left.
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used for more than a decade to image soft tissue 
infections and osteomyelitis.15 At the Royal Hospital, 
99mTc sulesomab has been used since 2013 to evaluate 
patients with total knee replacements for septic 
loosening. It is also valuable in detecting osteomyelitis 
in patients with sickle cell disease, particularly when 
a three-phase bone scan might yield a false-positive 
result in sites with regenerating bone marrow following 
vaso-occlusive crises.15
18F-FDG-PET/CT imaging is not yet available in 
Oman.16 Almost all oncology patients from the Royal 
Hospital are sent abroad for 18F-FDG-PET/CT imaging 
for initial staging and the evaluation of residual disease 
and treatment response. Currently, 67Ga citrate is 
used for the imaging of patients with PUO and the 
evaluation of patients with malignant otitis externa. In 
addition to a three-phase bone scan, 67Ga is also used 
to evaluate patients with total knee replacements for 
septic loosening. 
Conclusion 
Although the utilisation of 67Ga citrate has become 
less common with the introduction of new imaging 
modalities such as PET/CT and new radiotracers 
such as 99mTc, the findings of this study confirm 
that there is a continuing role for this radiotracer in 
infection and tumour imaging, particularly when PET/
CT facilities are not available. Furthermore, the results 
from this study were consistent with other reported 
rates of 67Ga scan sensitivity and specificity in the 
evaluation of lymphomas and infections.
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